Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 2,174 Shares

Key Points

• Insider sale: Director Jula Inrig sold 2,174 shares on May 5 at an average price of $46.65 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, part of a run of recent insider dispositions that included a 20,000‑share sale on May 4.
• Quarterly results: Travere reported Q1 EPS of $0.05 (beating the -$0.24 consensus) and revenue of $127.2M (up 55.6% YoY but slightly below estimates), which helped trigger multiple analyst price‑target raises and a consensus "Moderate Buy" with an average target of $47.83.
• Market context: TVTX traded near $44.70 (down ~0.2%), with a $4.16B market cap and a 12‑month range of $13.88–$48.61; investors should monitor continued insider activity and the company's leverage (debt/equity ~3.16).

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 2,174 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total transaction of $101,417.10. Following the transaction, the insider owned 113,549 shares of the company's stock, valued at approximately $5,297,060.85. This represents a 1.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, May 6th, Jula Inrig sold 311 shares of Travere Therapeutics stock. The shares were sold at an average price of $43.95, for a total transaction of $13,668.45.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $45.00, for a total transaction of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The shares were sold at an average price of $42.61, for a total transaction of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total transaction of $302,524.95.

Travere Therapeutics Stock Down 0.2%

Shares of Travere Therapeutics stock traded down $0.10 on Wednesday, hitting $44.70. The company had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. The firm has a market capitalization of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $48.61. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. The stock has a 50-day moving average of $32.59 and a 200-day moving average of $32.83.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.29. The company had revenue of $127.20 million during the quarter, compared to analysts' expectations of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business's quarterly revenue was up 55.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.47) earnings per share. Research analysts predict that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on TVTX. Wedbush upped their price target on shares of Travere Therapeutics from $53.00 to $55.00 and gave the company an "outperform" rating in a report on Tuesday. Piper Sandler upgraded shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price target for the company in a report on Tuesday, April 14th. Citigroup upped their price target on shares of Travere Therapeutics from $53.00 to $59.00 and gave the company a "buy" rating in a report on Tuesday. HC Wainwright upped their price target on shares of Travere Therapeutics from $47.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Travere Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $47.83.

Institutional Trading of Travere Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVTX. Stephens Investment Management Group LLC bought a new stake in Travere Therapeutics during the third quarter worth $38,232,000. State Street Corp raised its position in shares of Travere Therapeutics by 47.8% in the fourth quarter. State Street Corp now owns 4,756,666 shares of the company's stock valued at $181,752,000 after purchasing an additional 1,538,827 shares during the period. Wellington Management Group LLP raised its position in shares of Travere Therapeutics by 3,331.9% in the third quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company's stock valued at $28,715,000 after purchasing an additional 1,166,460 shares during the period. Fiera Capital Corp bought a new position in shares of Travere Therapeutics in the fourth quarter valued at about $33,398,000. Finally, Perceptive Advisors LLC bought a new position in shares of Travere Therapeutics in the second quarter valued at about $12,347,000.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.